AZ books 3 percent sales drop for Q3
AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.
Read More
Tag: Q3
New products boost Q3 sales at GSK
GlaxoSmithKline has posted a near 4 percent rise in sales for the third quarter of the year, driven by a solid performance by its HIV and respiratory therapies and a weak pound.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
